Trinity Biotech PLC SEC filings TRIB
Trinity Biotech PLC has 500 filings in SEC EDGAR's recent list, going back to Sep 9, 1996. Its latest annual report, Form 20-F, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Oct 5, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Sep 1, 2026 | — |
| AW | Filing | Aug 27, 2026 | — |
| EFFECT | Filing | Jun 10, 2026 | — |
| AW | Filing | Jun 4, 2026 | — |
| RW | Form rw | Jun 3, 2026 | — |
| EFFECT | Filing | May 22, 2026 | — |
| CORRESP | Letter to the SEC | May 20, 2026 | — |
| UPLOAD | Letter from the SEC | May 20, 2026 | — |
| EFFECT | Filing | Mar 3, 2026 | — |
| CORRESP | Letter to the SEC | Feb 27, 2026 | — |
| UPLOAD | Letter from the SEC | Feb 27, 2026 | — |
| UPLOAD | Letter from the SEC | Jan 27, 2026 | — |
| EFFECT | Filing | Jan 23, 2026 | — |
| CORRESP | Letter to the SEC | Jan 21, 2026 | — |
| NT 20-F | Filing | Apr 30, 2025 | Dec 31, 2024 |
| EFFECT | Filing | Mar 28, 2025 | — |
| CORRESP | Letter to the SEC | Mar 26, 2025 | — |
| UPLOAD | Letter from the SEC | Mar 26, 2025 | — |
| EFFECT | Filing | Dec 2, 2024 | — |
| CORRESP | Letter to the SEC | Nov 29, 2024 | — |
| UPLOAD | Letter from the SEC | Nov 21, 2024 | — |
| EFFECT | Filing | Jun 28, 2024 | — |
| CORRESP | Letter to the SEC | Jun 26, 2024 | — |
| UPLOAD | Letter from the SEC | Jun 25, 2024 | — |
| EFFECT | Filing | May 7, 2024 | — |
| CORRESP | Letter to the SEC | May 3, 2024 | — |
| UPLOAD | Letter from the SEC | May 2, 2024 | — |
| NT 20-F | Filing | May 1, 2023 | Dec 31, 2022 |
| EFFECT | Filing | Mar 29, 2023 | — |
| EFFECT | Filing | Sep 14, 2022 | — |
| CORRESP | Letter to the SEC | Sep 12, 2022 | — |
| UPLOAD | Letter from the SEC | Sep 6, 2022 | — |
| EFFECT | Filing | May 25, 2022 | — |
| CORRESP | Letter to the SEC | May 23, 2022 | — |
| UPLOAD | Letter from the SEC | May 23, 2022 | — |
| EFFECT | Filing | Jul 15, 2020 | — |
| CORRESP | Letter to the SEC | Jul 13, 2020 | — |
| UPLOAD | Letter from the SEC | Jul 10, 2020 | — |
| NT 20-F | Nt 20f | May 1, 2019 | Dec 31, 2018 |
| EFFECT | Filing | May 11, 2017 | — |
| CORRESP | Letter to the SEC | May 9, 2017 | — |
| UPLOAD | Letter from the SEC | Apr 27, 2015 | — |
| UPLOAD | Letter from the SEC | Jan 26, 2011 | — |
| CORRESP | Letter to the SEC | Dec 20, 2010 | — |
| UPLOAD | Letter from the SEC | Nov 23, 2010 | — |
| CORRESP | Letter to the SEC | Nov 5, 2010 | — |
| UPLOAD | Letter from the SEC | Sep 27, 2010 | — |
| UPLOAD | Letter from the SEC | Mar 17, 2010 | — |
| CORRESP | Letter to the SEC | Mar 5, 2010 | — |
| UPLOAD | Letter from the SEC | Feb 24, 2010 | — |
| CORRESP | Letter to the SEC | Feb 16, 2010 | — |
| UPLOAD | Letter from the SEC | Jan 6, 2010 | — |
| CORRESP | Letter to the SEC | Dec 21, 2009 | — |
| UPLOAD | Letter from the SEC | Dec 9, 2009 | — |
| CORRESP | Letter to the SEC | Nov 12, 2009 | — |
| CORRESP | Letter to the SEC | Oct 16, 2009 | — |
| UPLOAD | Letter from the SEC | Sep 9, 2009 | — |
| UPLOAD | Letter from the SEC | Feb 8, 2008 | — |
| CORRESP | Letter to the SEC | Jan 24, 2008 | — |
| CORRESP | Letter to the SEC | Nov 8, 2007 | — |
| UPLOAD | Letter from the SEC | Oct 17, 2007 | — |
| CORRESP | Letter to the SEC | Sep 28, 2007 | — |
| CORRESP | Letter to the SEC | Sep 11, 2007 | — |
| UPLOAD | Letter from the SEC | Feb 21, 2007 | — |
| CORRESP | Letter to the SEC | Jan 10, 2007 | — |
| CORRESP | Letter to the SEC | Dec 28, 2006 | — |
| UPLOAD | Letter from the SEC | Nov 28, 2006 | — |
| CORRESP | Letter to the SEC | Oct 6, 2006 | — |
| UPLOAD | Letter from the SEC | Sep 21, 2006 | — |
| CORRESP | Letter to the SEC | May 20, 2005 | — |
| UPLOAD | Letter from the SEC | May 9, 2005 | — |
| REGDEX | Auto-generated paper document | Jan 21, 2004 | — |
| RW | Request for withdrawal | Jul 25, 2003 | — |
| REGDEX | Auto-generated paper document | Jul 24, 2003 | — |
| NT 20-F | Form 12b25 for form 20-f fy 2002 | Jul 1, 2003 | Dec 31, 2002 |
Showing 75 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- TRIB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Ireland
- Headquarters
- Wicklow
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 888721
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
Source: SEC EDGAR filings. This is company-reported data, not investment advice.